Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

Rhea-AI Summary

Albireo Pharma, a company focused on rare liver diseases, will have its leadership team present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on August 10 at 3:30 p.m. ET. CEO Ron Cooper and CFO Simon Harford will share insights on its innovative bile acid modulators, including Bylvay, which is approved for treating progressive familial intrahepatic cholestasis (PFIC). The presentation can be accessed via Albireo’s website. This follows the company's ongoing Phase 3 trials for Alagille syndrome and biliary atresia, and its commitment to addressing cholestatic liver diseases.

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at 3:30 p.m. ET.

The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 30 days following the event.

About Albireo
Albireo Pharma is a rare liver disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s product, Bylvay, was approved by the U.S. FDA as the first for the treatment of pruritus in patients with all sub-types of progressive familial intrahepatic cholestasis (PFIC), and is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

When is Albireo Pharma's presentation at the Wedbush PacGrow Conference?

Albireo Pharma will present on August 10, 2021, at 3:30 p.m. ET.

Who will represent Albireo Pharma at the conference?

CEO Ron Cooper and CFO Simon Harford will represent Albireo Pharma at the conference.

How can I access the Albireo Pharma conference presentation?

The presentation will be available via a live webcast on Albireo's Media & Investors page.

What is Bylvay and what conditions does it treat?

Bylvay is approved for treating pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) and is in trials for other rare liver diseases.

What clinical trials is Albireo Pharma currently conducting?

Albireo is conducting Phase 3 trials for Alagille syndrome and biliary atresia, and has initiated a Phase 1 trial for A3907.

What recent achievements has Albireo Pharma accomplished?

Albireo has received FDA approval for Bylvay and was named one of the Best Places to Work in Massachusetts in 2020.